Latest news

  • 15 March 2023
    New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate elimination
    Model simulation shows cost of timely Voraxaze® use is offset by shorter hospital stays and associated with substantially improved clinical outcomes West Conshohocken, PA, 15 March 2023:  BTG Pharmaceuticals, a SERB company, today announces the publication of an economic simulation assessing the value of Voraxaze® (glucarpidase) for treating adult patients in the United States who […]
  • 19 October 2022
    SERB Presents Preclinical Data Showing Initial Efficacy of COVID-19 Treatment Developed with Polyclonal Antibody Platform
    Washington D.C., 19 October 2022: SERB Pharmaceuticals today announces preclinical data demonstrating initial efficacy of a new polyclonal, ovine fragment antibody (Fab) developed as a treatment for COVID-19. The data will be presented as a poster at IDWeek 2022, the annual meeting of the Infectious Diseases Society of America, held in Washington DC on October […]
  • 04 August 2022
    SERB Pharmaceuticals licenses Soligenix Antigen to Develop Ricin Antidote
    SERB Pharmaceuticals has signed a worldwide exclusive license to use an antigen from Soligenix [NSDQ: SNGX] to develop a novel therapeutic treatment for ricin poisoning. There is an unmet need for protection against this highly potent toxin for which there is no vaccine or therapeutic intervention available. To develop the ricin antidote, SERB will leverage its unique […]

News archive



    You are leaving the global corporate website
    This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
    Choose your region